

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63

Published online July 26, 2021

Online
Article

IN THIS ISSUE

In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 63

Published online July 26, 2021

Online
Article

IN THIS ISSUE

In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines

IN BRIEF

Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines

On June 25, 2021, the FDA added a warning to the Fact Sheets for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (*Comirnaty*) and Moderna (*Spikevax*) about an increased risk of myocarditis and pericarditis following administration of the vaccines.^{1,2}

The warning was issued after a review of reports to the Vaccine Adverse Events Reporting System (VAERS) submitted between December 29, 2020 and June 11, 2021 identified 1226 cases of myocarditis following administration of an mRNA vaccine. Cases occurred most commonly in males (76%), in persons <30 years old (58%), and after administration of the second vaccine dose (76%). Symptoms usually developed within a few days after vaccination. At the time of the review, about 296 million doses of mRNA-based COVID-19 vaccines had been administered in the US, including 52 million doses in persons <30 years old.^{3,4}

A CDC analysis of 323 cases of myocarditis following mRNA vaccination in persons 16-29 years old found that 90% of cases were in males and 96% required hospitalization. The median time to symptom onset after vaccination was 2 days. Most cases were mild in severity, and none of the 304 patients with known clinical outcomes died. The CDC estimates that, for every 1 million males 12-29 years old who receive a 2-dose mRNA-based COVID-19 vaccination series, 560 hospitalizations due to COVID-19 would be prevented and 39-47 cases of myocarditis would occur.⁴

The Advisory Committee on Immunization Practices (ACIP) concluded in a June 23, 2021 meeting that the benefits of mRNA-based COVID-19 vaccination still clearly outweigh the risks for all persons ≥ 12 years old.⁵ Adolescents and young adults who experience acute chest pain, shortness of breath, or palpitations after vaccination should be assessed with an ECG, a troponin level, and inflammatory marker testing (e.g., C-reactive protein level, erythrocyte sedimentation rate).⁶ Myocarditis has not been associated with use of the adenovirus-based Johnson & Johnson (Janssen) COVID-19 vaccine to date. ■

1. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). June 25, 2021. Available at: <https://bit.ly/37fX1NG>. Accessed July 21, 2021.
2. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). June 24, 2021. Available at: <https://bit.ly/3nosylA>. Accessed July 21, 2021.
3. FDA News Release. Coronavirus (COVID-19) update: June 25, 2021. Available at: <https://bit.ly/3Bp7TpK>. Accessed July 21, 2021.
4. JW Gargano et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices – United States, June 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70:977.
5. CDC. ACIP live meeting archive – June 2021. Available at: <https://bit.ly/3ruraBt>. Accessed July 21, 2021.
6. CDC. Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. May 28, 2021. Available at: <https://bit.ly/3xZqlmQ>. Accessed July 21, 2021.

Online Tables: COVID-19 Treatments and Vaccines

Please check our website for the latest information on COVID-19, including our continuously updated tables: Treatments Considered for COVID-19 and COVID-19 Vaccine Comparison Chart. Available at: www.medicalletter.org/drugs-for-covid-19.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:  

Copyright 2021. ISSN 0025-732X

The
Medical
Letter